Cobicistat: A case of mislabelled drug-drug interaction risk?
作者信息
Burger David M, Calmy Alexandra, Marzolini Catia
机构信息
Department of Pharmacy, Radboud Institute for Health Sciences, Radboud University Medical Center, Nijmegen, The Netherlands.
HIV/AIDS Unit, Division of Infectious Diseases, Geneva University Hospitals, Geneva, Switzerland.
出版信息
Br J Clin Pharmacol. 2020 May;86(5):834-836. doi: 10.1111/bcp.14262. Epub 2020 Mar 6.
Abstract
摘要
相似文献
1
Cobicistat: A case of mislabelled drug-drug interaction risk?考比司他：一例药物标签错误导致的药物相互作用风险病例？
Br J Clin Pharmacol. 2020 May;86(5):834-836. doi: 10.1111/bcp.14262. Epub 2020 Mar 6.
2
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.考比司他：一种用于HIV感染的药代动力学增强剂的综述。
Clin Ther. 2015 Sep 1;37(9):1876-93. doi: 10.1016/j.clinthera.2015.07.022. Epub 2015 Aug 25.
3
Cobicistat versus ritonavir boosting and differences in the drug-drug interaction profiles with co-medications.考比司他与利托那韦增效作用的比较及与合并用药药物相互作用特征的差异。
J Antimicrob Chemother. 2016 Jul;71(7):1755-8. doi: 10.1093/jac/dkw032. Epub 2016 Mar 5.
4
Darunavir-cobicistat-emtricitabine-tenofovir alafenamide: safety and efficacy of a protease inhibitor in the modern era.达芦那韦-考比司他-恩曲他滨-替诺福韦艾拉酚胺：现代蛋白酶抑制剂的安全性与疗效
Drug Des Devel Ther. 2018 Oct 29;12:3635-3643. doi: 10.2147/DDDT.S147493. eCollection 2018.
5
Darunavir/cobicistat once daily for the treatment of HIV.达芦那韦/考比司他每日一次用于治疗HIV。
Expert Rev Anti Infect Ther. 2015 Jun;13(6):691-704. doi: 10.1586/14787210.2015.1033400.
6
Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS.达芦那韦-考比司他组合在治疗HIV/AIDS中的原理及临床应用
Drug Des Devel Ther. 2015 Oct 23;9:5763-9. doi: 10.2147/DDDT.S63989. eCollection 2015.
7
Pharmacokinetic interactions between cobicistat-boosted elvitegravir and darunavir in HIV-infected patients.在HIV感染患者中，考比司他增强的埃替格韦与达芦那韦之间的药代动力学相互作用。
J Antimicrob Chemother. 2017 Mar 1;72(3):816-819. doi: 10.1093/jac/dkw487.
8
Factors associated with the number of drugs in darunavir/cobicistat regimens.与达芦那韦/考比司他方案中药物种类相关的因素。
J Antimicrob Chemother. 2020 Jan 1;75(1):208-214. doi: 10.1093/jac/dkz399.
9
Cobicistat, a pharmacoenhancer for HIV treatments.考比司他，一种用于治疗艾滋病的药物增强剂。
Drugs Today (Barc). 2013 Apr;49(4):233-7. doi: 10.1358/dot.2013.49.4.1947288.
10
Exogenous steroid-induced hypoadrenalism in a person living with HIV caused by a drug-drug interaction between cobicistat and intrabursal triamcinolone.由考比司他与囊内注射曲安奈德之间的药物相互作用导致的HIV感染者外源性类固醇诱导的肾上腺功能减退。
BMJ Case Rep. 2018 Dec 14;11(1):e226912. doi: 10.1136/bcr-2018-226912.
引用本文的文献
1
PBPK Modeling of Lamotrigine and Efavirenz during Pregnancy: Implications for Personalized Dosing and Drug-Drug Interaction Management.孕期拉莫三嗪和依非韦伦的生理药代动力学（PBPK）模型：对个体化给药和药物相互作用管理的启示
Pharmaceutics. 2024 Sep 3;16(9):1163. doi: 10.3390/pharmaceutics16091163.
2
Clinical Relevance of Drug Interactions in People Living with Human Immunodeficiency Virus on Antiretroviral Therapy-Update 2022: Systematic Review.接受抗逆转录病毒治疗的人类免疫缺陷病毒感染者中药物相互作用的临床相关性——2022年更新：系统评价
Pharmaceutics. 2023 Oct 18;15(10):2488. doi: 10.3390/pharmaceutics15102488.
3
Cytochrome P450 Enzymes as Drug Targets in Human Disease.细胞色素 P450 酶作为人类疾病的药物靶点。
Drug Metab Dispos. 2024 May 16;52(6):493-497. doi: 10.1124/dmd.123.001431.
4
[Rhabdomyolysis due to drug-drug interaction of atorvastatin and cobicistat].[阿托伐他汀与考比司他药物相互作用导致的横纹肌溶解症]
Inn Med (Heidelb). 2022 Nov;63(11):1189-1193. doi: 10.1007/s00108-022-01377-x. Epub 2022 Aug 24.
5
Dexamethasone is a dose-dependent perpetrator of drug-drug interactions: implications for use in people living with HIV.地塞米松是一种剂量依赖性的药物相互作用的促成剂：对 HIV 感染者的应用的影响。
J Antimicrob Chemother. 2022 Feb 23;77(3):568-573. doi: 10.1093/jac/dkab412.
6
Lopinavir/Ritonavir and Darunavir/Cobicistat in Hospitalized COVID-19 Patients: Findings From the Multicenter Italian CORIST Study.洛匹那韦/利托那韦与达芦那韦/考比司他用于住院COVID-19患者：多中心意大利CORIST研究的结果
Front Med (Lausanne). 2021 Jun 9;8:639970. doi: 10.3389/fmed.2021.639970. eCollection 2021.
7
Pharmacological agents under investigation in the treatment of coronavirus disease 2019 and the importance of melatonin.正在研究用于治疗 2019 年冠状病毒病的药物及褪黑素的重要性。
Fundam Clin Pharmacol. 2021 Feb;35(1):62-75. doi: 10.1111/fcp.12589. Epub 2020 Oct 14.
本文引用的文献
1
Reduced exposure to darunavir and cobicistat in HIV-1-infected pregnant women receiving a darunavir/cobicistat-based regimen.HIV-1 感染孕妇接受基于达芦那韦/考比司他方案治疗时，达芦那韦和考比司他的暴露量降低。
HIV Med. 2019 May;20(5):337-343. doi: 10.1111/hiv.12721. Epub 2019 Mar 14.
2
Elvitegravir/cobicistat pharmacokinetics in pregnant and postpartum women with HIV.HIV 感染孕妇及产后女性中埃替拉韦/考比司他的药代动力学。
AIDS. 2018 Nov 13;32(17):2507-2516. doi: 10.1097/QAD.0000000000001992.
3
Cobicistat Versus Ritonavir: Similar Pharmacokinetic Enhancers But Some Important Differences.考比司他与利托那韦：相似的药代动力学增强剂，但存在一些重要差异。
Ann Pharmacother. 2017 Nov;51(11):1008-1022. doi: 10.1177/1060028017717018. Epub 2017 Jun 19.
4
Boosting axitinib exposure with a CYP3A4 inhibitor, making axitinib treatment personal.使用CYP3A4抑制剂提高阿昔替尼的血药浓度，实现阿昔替尼治疗的个体化。
Acta Oncol. 2017 Sep;56(9):1238-1240. doi: 10.1080/0284186X.2017.1311024. Epub 2017 Apr 7.
5
Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.抗逆转录病毒增效剂考比司他可增加达比加群在HIV阴性健康志愿者体内的药代动力学暴露量及抗凝效果。
Circulation. 2016 Dec 6;134(23):1909-1911. doi: 10.1161/CIRCULATIONAHA.116.025257.
6
Oral administration of procaine penicillin with and without benemid [p-(DI-n-propylsulphamyl) benzoic acid].口服普鲁卡因青霉素，分别加与不加丙磺舒 [对-（二正丙基氨磺酰基）苯甲酸]。
Lancet. 1951 Jul 21;2(6673):104-6. doi: 10.1016/s0140-6736(51)91356-6.
7
Cyclosporine-ketoconazole combination offers promise in reducing antirejection therapy costs.环孢素与酮康唑联合使用有望降低抗排斥治疗成本。
JAMA. 1990 Jul 25;264(4):430-1.
Zotero 插件